Large-Scale Multicenter Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China

This study assessed the efficacy and safety of ripretinib in 240 Chinese patients with advanced gastrointestinal stromal tumors (GIST) as a fourth-line or later treatment. The median progression-free survival (mPFS) was 7.7 months, and the median overall survival (mOS) was not reached at a median follow-up of 6.5 months. Non-gastric GIST patients had a better outcome with a hazard ratio (HR) of 0.58. The disease control rate was 73%, with tumor shrinkage in 43% of patients. Ripretinib was effective across various gene mutations and was well-tolerated, with alopecia (17.1%) and hand-foot syndrome (15.4%) being the most common adverse events. The study concluded that ripretinib is an effective and safe treatment for advanced GIST in the Chinese population, especially for non-gastric GISTs, and it also improved or stabilized patient-reported quality of life outcomes. Limitations include the observational nature of the study and its focus on a Chinese cohort, which may limit the generalizability of the findings. No funding or conflicts of interest were reported, and the study adhered to ethical standards.